非酒精性脂肪性肝病(Non-alcoholic fatty liver disease, NAFLD)包括一系列的肝脏表现,从肝脏脂肪变性开始,可能演变为非酒精性脂肪性肝炎(Non-alcoholic steatohepatitis, NASH)、纤维化、肝硬化甚至肝细胞癌(Hepatocellular carcinoma, HCC)。其发病率在全球范围内呈上升趋势。尽管NAFLD是一种与代谢紊乱相关的疾病,但它也涉及多种免疫细胞介导的炎症过程。多种免疫细胞通过分泌促炎或抗炎因子来促进或抑制肝细胞炎症,从而影响NAFLD进程。T细胞作为适应性免疫中重要的一环,包括多种淋巴细胞亚群,在NAFLD的进展中发挥着关键作用。本文综述了T淋巴细胞亚群在NAFLD发病机制中的作用,以期为非酒精性脂肪性肝病的药物干预提供新策略。Non-alcoholic fatty liver disease (NAFLD) encompasses a series of liver manifestations. Starting from hepatic steatosis, it may progress to non-alcoholic steatohepatitis (NASH), fibrosis, liver cirrhosis and even hepatocellular carcinoma (HCC). The incidence of NAFLD is on the rise globally. Although NAFLD is a disease concerning metabolic disorders, it also involves various inflammatory processes mediated by immune cells. Various immune cells promote or inhibit liver cell inflammation by secreting pro-inflammatory or anti-inflammatory factors to influence the progression of non-alcoholic fatty liver disease (NAFLD). T cells, as an important part of adaptive immunity, include multiple lymphocyte subsets and play a crucial role in the progression of NAFLD. We review the roles of T lymphocyte subsets in the pathogenesis of NAFLD, expecting to provide new strategies for the pharmaceutical intervention of non-alcoholic fatty liver disease.
暂无评论